Alexion shelves an early-stage Sanfilippo B drug, writes off $85M
When Alexion bought out Synageva in an $8.4 billion deal a little less than two years ago, the big attraction was Kanuma, a rare disease …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
